JP2017506233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506233A5 JP2017506233A5 JP2016550629A JP2016550629A JP2017506233A5 JP 2017506233 A5 JP2017506233 A5 JP 2017506233A5 JP 2016550629 A JP2016550629 A JP 2016550629A JP 2016550629 A JP2016550629 A JP 2016550629A JP 2017506233 A5 JP2017506233 A5 JP 2017506233A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- creatine
- omega
- disorder
- depressive disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937328P | 2014-02-07 | 2014-02-07 | |
| US61/937,328 | 2014-02-07 | ||
| PCT/US2015/014856 WO2015120299A1 (en) | 2014-02-07 | 2015-02-06 | Combination of creatine, an omega-3 fatty acid, and citicoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506233A JP2017506233A (ja) | 2017-03-02 |
| JP2017506233A5 true JP2017506233A5 (enExample) | 2018-03-22 |
Family
ID=53778486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550629A Pending JP2017506233A (ja) | 2014-02-07 | 2015-02-06 | クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10058552B2 (enExample) |
| EP (1) | EP3102227A4 (enExample) |
| JP (1) | JP2017506233A (enExample) |
| KR (1) | KR20160137528A (enExample) |
| CN (1) | CN106102765A (enExample) |
| WO (1) | WO2015120299A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160137528A (ko) | 2014-02-07 | 2016-11-30 | 유니버시티 오브 유타 리서치 파운데이션 | 크레아틴, 오메가-3 지방산 및 시티콜린의 조합 |
| US11160982B2 (en) * | 2017-07-05 | 2021-11-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating post-traumatic stress disorder in patients via renal neuromodulation |
| KR102269106B1 (ko) | 2017-11-20 | 2021-06-24 | 주식회사 엘지화학 | 배터리 파워 한계 값 제어 방법 |
| EP3563830A1 (en) | 2018-05-03 | 2019-11-06 | Commissariat à l'énergie atomique et aux énergies alternatives | Micro-emulsion containing creatine fatty ester, method for preparing said micro-emulsion and uses thereof |
| KR102141737B1 (ko) * | 2018-10-23 | 2020-08-05 | 이화여자대학교 산학협력단 | 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물 |
| EP3732995A1 (en) * | 2019-04-30 | 2020-11-04 | Commissariat à l'énergie atomique et aux énergies alternatives | Composition containing creatine fatty ester for use in medicine |
| EP4522145A1 (en) * | 2022-05-12 | 2025-03-19 | AlzChem Trostberg GmbH | Composition comprising creatine for use in the treatment of post viral fatigue syndrome |
| IT202300026181A1 (it) * | 2023-12-06 | 2025-06-06 | Hope S R L | Potenziata composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi quali parkinson e halzheimer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0956013T3 (da) | 1996-10-11 | 2003-08-04 | Scarista Ltd | Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| DE19929995B4 (de) | 1999-06-30 | 2004-06-03 | Skw Trostberg Ag | Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen |
| WO2001068104A1 (en) | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| ATE457726T1 (de) * | 2002-06-19 | 2010-03-15 | Nutricia Nv | Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen |
| AU2004317087A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US7776915B2 (en) | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| DE102006016227A1 (de) | 2006-04-06 | 2007-10-11 | Degussa Gmbh | Verfahren zur Herstellung von Kreatin, Kreatin-Monohydrat oder Guanidinoessigsäure |
| US20110274680A1 (en) * | 2009-10-02 | 2011-11-10 | Mazed Mohammad A | Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases |
| US8563609B2 (en) * | 2010-05-13 | 2013-10-22 | Nitromega Corp. | Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline |
| US20130281410A1 (en) | 2010-05-13 | 2013-10-24 | University Of Utah Research Foundation | Methods for the treatment of psychiatric disorders |
| US20130324609A1 (en) * | 2010-10-08 | 2013-12-05 | University Of Utah Research Foundation | Depression disorder therapeutics with creatine analogs |
| KR20160137528A (ko) | 2014-02-07 | 2016-11-30 | 유니버시티 오브 유타 리서치 파운데이션 | 크레아틴, 오메가-3 지방산 및 시티콜린의 조합 |
-
2015
- 2015-02-06 KR KR1020167024567A patent/KR20160137528A/ko not_active Ceased
- 2015-02-06 WO PCT/US2015/014856 patent/WO2015120299A1/en not_active Ceased
- 2015-02-06 EP EP15746527.9A patent/EP3102227A4/en not_active Withdrawn
- 2015-02-06 US US15/117,143 patent/US10058552B2/en not_active Expired - Fee Related
- 2015-02-06 CN CN201580013800.XA patent/CN106102765A/zh active Pending
- 2015-02-06 JP JP2016550629A patent/JP2017506233A/ja active Pending
-
2018
- 2018-03-08 US US15/916,140 patent/US10265317B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506233A5 (enExample) | ||
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| Kaur et al. | Short-term docosapentaenoic acid (22: 5n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats | |
| NZ600740A (en) | Compositions containing pufa and/or uridine and methods of use thereof | |
| JP2012516852A5 (enExample) | ||
| US6340705B1 (en) | Use of α-linolenic acid metabolites for treatment or prevention of cancer | |
| ZA202110659B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| JP2019048843A5 (enExample) | ||
| JP2015147773A5 (enExample) | ||
| NZ727980A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| JP2020500193A5 (enExample) | ||
| JP2015143248A5 (enExample) | ||
| JP2013521310A5 (enExample) | ||
| JP2016516040A5 (enExample) | ||
| CA2877514C (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| HK1204272A1 (en) | Methods of treating pediatric metabolic syndrome | |
| JP2020500875A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| JP2016053065A5 (enExample) | ||
| JP2014515011A5 (enExample) | ||
| MX2020002238A (es) | Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias. | |
| BR112017027909A2 (pt) | composição, e, uso de uma composição | |
| JP2020182497A5 (enExample) | ||
| EA201100143A1 (ru) | Длительное лечение клинически выраженной сердечной недостаточности |